Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVP-001 in healthy adult volunteers
NCT05413668Phase 1Completed
- Sponsor
- Reveal Pharmaceuticals
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing RVP-001 with Placebo (2 arms). Primary endpoints: Safety and tolerability of single ascending doses, Pharmacokinetic (PK) Parameter Cmax at 120 hours and 4 more. Started May 2022; status: completed.
02
Drugs
manganese-based contrast agent RVP-001
Beyond the preview
Go deeper on NCT05413668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05413668.